中国经济网北京6月10日讯 安奈儿(002875.SZ)今日复牌，收报16.08元，跌幅4.85%，总市值34.25亿元。 停牌前一个交易日，即5月30日，安奈儿涨停收报16.90元，涨幅10.03%。 本次权益变动后，新创源将成为公司的控股股东，黄涛将成为公司的实际控制人。 昨日晚间，安奈儿发布关于筹划公司控制权变更事项的进展暨复牌公告。此前公司收到控股股东、实际 控制人曹璋、王建青的通知，获悉其正在筹划公司控制权变更相关事项，曹璋和王建青拟通过向交易对 手方转让公司股份等方式，使交易对手方获得公司控制权。具体转让比例和实施方案尚待进一步沟通确 定。本次的交易对手方主要从事投资管理业务。若本次交易完成后，公司的控股股东、实际控制人将发 生变更。 财务数据显示，2020年安奈儿实现归属净利润约为-4681.59万元，自此之后公司业绩一直未能扭亏。 2021年至2024年，安奈儿实现归属净利润分别约为-302.95万元、-2.37亿元、-9955.15万元、-1.15亿元。 今年一季度，安奈儿实现归属于上市公司股东的净利润为-833.33万元。 鉴于上述事项尚存在重大不确定性，为保证公平信息披露，维护投资者利益 ...

Core Viewpoint - The company, Palin Bio (000403.SZ), has resumed trading after announcing a significant change in control, with its major shareholder, Shengbang Yinghao, planning to transfer 21.03% of its shares to China National Pharmaceutical Group (China Bio) [1][2]. Group 1: Stock Performance - Upon resuming trading, the stock opened at a limit-up price of 18.66 yuan, reflecting a 10.02% increase, but closed at 17.14 yuan, with a final gain of 1.06% [1]. Group 2: Control Change Announcement - The transfer of shares will result in a change of the controlling shareholder from Shengbang Yinghao to China Bio, and the actual controller will shift from the Shaanxi Provincial Government's State-owned Assets Supervision and Administration Commission to China National Pharmaceutical Group [1][2]. - The company has stated that this change in control will not adversely affect its normal operations and will not harm the interests of the company or minority shareholders [2]. Group 3: Due Diligence and Regulatory Requirements - Following the signing of the acquisition framework agreement, China Bio will conduct due diligence, and the completion of this process is necessary before any further agreements can be signed [2]. - The transaction is subject to compliance confirmation from the Shenzhen Stock Exchange and must undergo share transfer registration with the China Securities Depository and Clearing Corporation [2].

Group 1 - Anner plans to change its controlling shareholder to Shenzhen Xinchuangyuan Investment Partnership, with Huang Tao as the actual controller [2][5][7] - The share transfer agreement involves Cao Zhang and Wang Jianqing transferring 4.78% and 8.25% of their shares respectively to Xinchuangyuan at a price of 15.21 yuan per share, totaling 422 million yuan [5][7] - Following the transaction, Xinchuangyuan will hold 13.03% of Anner's shares and gain corresponding voting rights, while Cao Zhang will retain 14.35% of the shares but waive voting rights [7][8] Group 2 - Xinchuangyuan was established on May 27, with a registered capital of 395 million yuan, primarily engaged in investment management [8][9] - Huang Tao, the actual controller of Xinchuangyuan, is also the actual controller of Century Jinyuan Group, which has previously been involved in acquiring control of Wantu Technology [3][9] - Anner's stock price surged by 17.69% from May 28 to May 30, coinciding with the announcement of the change in control [13] Group 3 - Anner has been experiencing a decline in revenue, with a reported 20.70% decrease in revenue from 2023 to 2024, and a net loss of 114.66 million yuan in 2024 [14] - The company plans to adjust its store structure and enhance its online presence to develop a "super comfortable Anner" brand image over the next 3 to 5 years [15]

证券代码：002875 证券简称：安奈儿 公告编号：2025-030 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 奈儿，股票代码：002875）自 2025 年 6 月 10 日（星期二）开市起复牌。 广大投资者注意投资风险。 一、停牌事项 此前公司收到控股股东、实际控制人曹璋先生、王建青女士的通知，获悉其 正在筹划公司控制权变更相关事项，曹璋先生和王建青女士拟通过向交易对手方 转让公司股份等方式，使交易对手方获得公司控制权。具体转让比例和实施方案 尚待进一步沟通确定。本次的交易对手方主要从事投资管理业务。若本次交易完 成后，公司的控股股东、实际控制人将发生变更。 鉴于上述事项尚存在重大不确定性，为保证公平信息披露，维护投资者利益， 避免造成公司股价异常波动，根据《深圳证券交易所股票上市规则》《深圳证券 交易所上市公司自律监管指引第 6 号——停复牌》等有关规定，经公司向深圳证 券交易所申请，公司股票（股票简称：安奈儿，股票代码：002875）自 2025 年 年 6 月 5 日刊登在《证券时报》《中国证券报》及巨潮资讯网 深圳市安奈儿股份有限 ...

安奈儿(002875.SZ)公告称，公司控股股东、实际控制人曹璋、王建青与深圳新创源投资合伙企业（有 限合伙）签署了《股份转让协议》，拟通过转让公司股份的方式，使新创源获得公司控制权。公司股票 将于2025年6月10日开市起 复牌。本次交易事项尚需经尽职调查、交易所合规性审核及办理股份协议转 让过户相关手续，存在重大不确定性。 ...

Overview of the Transaction - The controlling shareholder of the company, Pailin Biopharmaceutical Co., Ltd., is set to change from Shengbang Yinghao Investment Partnership to China National Pharmaceutical Group Co., Ltd. [1][8] - Shengbang Yinghao holds 21.03% of the company's shares, all of which are tradable shares [2][8]. Parties Involved - The transferor is Shengbang Yinghao Investment Partnership, located in Jiangxi Province, with a capital contribution of 500 million yuan [2][5]. - The transferee is China National Pharmaceutical Group Co., Ltd., based in Beijing, with a registered capital of approximately 980.82 million yuan [2][5]. Key Terms of the Agreement - The acquisition framework agreement was signed on June 8, 2025, with a transfer price of approximately 384.38 million yuan, plus interest calculated at an annual rate of 9% from March 20, 2023, until the formal transaction documents are signed [5][6]. - The agreement stipulates that the number of shares may be adjusted in case of corporate actions like stock splits or dividends [5]. Due Diligence and Compliance - The agreement is contingent upon the completion of due diligence by the transferee, and the final transaction amount will be determined in the formal share transfer agreement [6][9]. - The transaction requires compliance confirmation from the Shenzhen Stock Exchange and other regulatory approvals [9]. Impact on the Company - The transaction is not expected to adversely affect the company's normal operations or the interests of minority shareholders [8][9]. - The transaction does not constitute a tender offer or related party transaction [8].

Core Viewpoint - The announcement of a potential change in control at Zhongying Electronics raises uncertainties regarding its future strategic direction and leadership, particularly with the possible departure of founder Fu Qiming, who has significantly influenced the company's growth and market positioning in the integrated circuit design sector [1][8]. Group 1: Company Overview - Zhongying Electronics specializes in integrated circuit design, operating under a fabless model, focusing on chip design, research, and sales [4]. - As of 2024, the company reported a revenue of 1.343 billion yuan, reflecting a slight year-on-year increase of 3.32%, indicating its competitive market position despite a challenging environment [4]. - The net profit attributable to shareholders was 134 million yuan, showing a decrease due to a one-time compensation received in the previous reporting period, suggesting a more favorable profit trend when excluding this non-recurring item [4]. Group 2: Product Performance - From 2022 to 2024, the total sales volume of chips increased steadily from 713 million to 885 million units, marking a nearly 9% year-on-year growth in 2024, indicating rising market demand [5]. - The company's gross margin was reported at 33.60%, down 2.01% year-on-year, primarily due to intense market competition and price reductions [5]. Group 3: Product Structure and Market Position - Zhongying Electronics' main products include industrial MCUs, battery management chips, and AMOLED display driver chips, with a strong market share in the industrial MCU sector, particularly in household appliances [6]. - The company has developed several 32-bit Cortex M0+ products for the home appliance market and is expanding its overseas market presence, including new clients in Europe and Japan [6][7]. Group 4: Research and Development - In 2024, the company invested 300 million yuan in R&D, accounting for 22.35% of its revenue, although this figure has seen a slight decline over three consecutive years [7]. - Zhongying Electronics holds a total of 135 valid patents, with 133 being invention patents, showcasing its commitment to innovation and technological advancement [7]. Group 5: Leadership and Strategic Implications - The potential change in control involving Weilang International could lead to significant strategic adjustments for Zhongying Electronics, especially if Fu Qiming exits the decision-making team [8]. - The future trajectory of the company remains uncertain, with the possibility of either leveraging new shareholder support for growth or facing challenges during the transition [8].

Group 1 - The company, Tibet Yiming Xiya Pharmaceutical Technology Co., Ltd., experienced abnormal stock trading fluctuations on June 5 and June 6, 2025, as per the relevant regulations [1] - The board of directors confirmed that there are no undisclosed significant matters affecting the company's stock price, apart from the disclosed share transfer agreement with Beijing Fuhai, which involves the acquisition of 43,855,883 shares from the controlling shareholder Gao Fan [1][2] - The company has disclosed the necessary documents regarding the change of control, including a brief and detailed report on equity changes, and has confirmed that there are no other undisclosed matters that could impact the stock price [2] Group 2 - The company will continue to comply with legal and regulatory requirements for information disclosure and will ensure timely updates regarding any significant changes [2] - The completion of the equity change is subject to compliance confirmation from the Shenzhen Stock Exchange and other necessary approvals, indicating potential uncertainties in the implementation of the transaction [2]

Core Viewpoint - Honghui Fruits and Vegetables (stock code: 603336) is planning a share transfer that may lead to a change in control of the company, as notified by its controlling shareholder Huang Junhui [1][3]. Group 1: Company Overview - Honghui Fruits and Vegetables was established in 1992 and is headquartered in Shantou, Guangdong Province. It was listed on the Shanghai Stock Exchange on November 24, 2016, and is recognized as a key leading enterprise in agricultural industrialization [3][4]. - The company operates under several well-known brands, including "Honghui Fruits and Vegetables," "Honghui Food," and "Monkey Community," with a presence in various regions including Guangdong, Shanghai, and overseas in Malaysia [4]. Group 2: Business Operations - Honghui Fruits and Vegetables specializes in the management of fruit and vegetable products, including post-harvest acquisition, cold chain storage, processing, and distribution. It also engages in the production and distribution of frozen foods and edible oils [4]. Group 3: Financial Performance - In the 2024 annual report, the company reported a revenue of 1.08 billion yuan, a decrease of 0.52% year-on-year, and a net profit attributable to shareholders of 18.30 million yuan, down 23.59% year-on-year [4]. - The 2025 Q1 report indicated a revenue of 246 million yuan, an increase of 13.71% year-on-year, but a net profit of approximately 4.50 million yuan, a decline of 44.38% year-on-year, primarily due to falling sales prices in the fruit business [4]. Group 4: Market Performance - As of June 6, the stock price of Honghui Fruits and Vegetables was 6.24 yuan per share, with a total market capitalization of 3.56 billion yuan. The stock has seen a cumulative increase of 46.14% since the beginning of the year [5].

Core Viewpoint - The leading bathroom company, Diao Home, is at a critical juncture, potentially facing a change in control as its major shareholders plan to alter their unified action [1][3]. Group 1: Company Background and Control Change - Diao Home's major shareholders, Liu Jin, Chen Wei, and Wu Zhixiong, are considering a change in control, which may involve the actual controller of Chengdu Shuihua Zhiyun Technology Co., Ltd., Zhu Jiang [1][4]. - The company was founded in the 1990s by Liu Jin, Chen Wei, and Wu Zhixiong, who initially made their fortune in agate before transitioning to the acrylic sanitary ware market [7][8]. - Diao Home, previously known as Diwang Sanitary Ware, went public in 2016 and later acquired the ceramic giant Oushennuo, rebranding itself as Diao Home [1][8]. Group 2: Financial Performance - Diao Home's market value has plummeted by over 10 billion, with revenue dropping from 6.147 billion in 2021 to 2.741 billion in 2024, marking a significant decline [1][11]. - The company's net profit has been in a continuous loss for three years, with losses of 1.509 billion, 658 million, and 569 million recorded from 2022 to 2024 [11][12]. - The revenue from both distribution and engineering channels has decreased, with the engineering channel seeing a staggering 51.93% drop in 2024 [11]. Group 3: Management and Employee Trends - Despite the declining performance, the total compensation for the management team has increased, contrasting with a reduction in employee numbers from 6,848 in 2021 to 3,942 in 2024 [2][14]. - The management's total pre-tax compensation rose from 4.4278 million in 2021 to 6.6734 million in 2024, while the number of employees decreased significantly [14]. Group 4: Future Outlook - Diao Home's stock price has fallen over 80% from its peak of 43.7 yuan per share, with a current market value of only 2.243 billion [14]. - The potential change in control raises questions about whether the company can revitalize under new leadership [14].